Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 5 (2008), Issue 7 (July)

1. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis.
   JAMA, 300(1): 71-80. [Abstract] [Full-text]
2. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization.
   Am J Health Syst Pharm, 65(14): 1347-57. [Abstract] [Full-text]
3. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.
   Clin Cancer Res, 14(13): 4219-24. [Abstract] [Full-text]
4. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.
   Clin Cancer Res, 14(13): 4213-8. [Abstract] [Full-text]
5. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).
   Clin Cancer Res, 14(13): 4192-9. [Abstract] [Full-text]
6. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
   Cancer Res, 68(13): 5236-45. [Abstract] [Full-text]
7. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches.
   Cancer Res, 68(13): 5226-35. [Abstract] [Full-text]
8. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies.
   Cancer Res, 68(13): 4998-5003. [Abstract] [Full-text]
9. iASPP inhibition: increased options in targeting the p53 family for cancer therapy.
   Cancer Res, 68(13): 4959-62. [Abstract] [Full-text]
10. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.
    Br J Cancer, 99(1): 93-9. [Abstract] [Full-text]
11. Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer.
    Br J Cancer, 99(1): 57-62. [Abstract] [Full-text]
12. The cost-effectiveness of thrombolysis administered by paramedics.
    Curr Med Res Opin, 24(7): 2045-58. [Abstract] [Full-text]
13. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.
    Br J Cancer, 99(1): 44-50. [Abstract] [Full-text]
14. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
    Br J Cancer, 99(1): 51-6. [Abstract] [Full-text]
15. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study.
    Curr Med Res Opin, 24(7): 1905-17. [Abstract] [Full-text]
16. Turning off frequently overridden drug alerts: limited opportunities for doing it safely.
    J Am Med Inform Assoc, 15(4): 439-48. [Abstract] [Full-text]
17. Identifying and quantifying medication errors: evaluation of rapidly discontinued medication orders submitted to a computerized physician order entry system.
    J Am Med Inform Assoc, 15(4): 461-5. [Abstract] [Full-text]
18. Evaluation of an inpatient computerized medication reconciliation system.
    J Am Med Inform Assoc, 15(4): 449-52. [Abstract] [Full-text]
19. Costs associated with developing and implementing a computerized clinical decision support system for medication dosing for patients with renal insufficiency in the long-term care setting.
    J Am Med Inform Assoc, 15(4): 466-72. [Abstract] [Full-text]
20. A randomized trial of the effectiveness of on-demand versus computer-triggered drug decision support in primary care.
    J Am Med Inform Assoc, 15(4): 430-8. [Abstract] [Full-text]
21. Workarounds to barcode medication administration systems: their occurrences, causes, and threats to patient safety.
    J Am Med Inform Assoc, 15(4): 408-23. [Abstract] [Full-text]
22. A risk analysis method to evaluate the impact of a computerized provider order entry system on patient safety.
    J Am Med Inform Assoc, 15(4): 453-60. [Abstract] [Full-text]
23. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan.
    Anticancer Drugs, 19(7): 753-9. [Abstract] [Full-text]
24. Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study.
    Anticancer Drugs, 19(7): 749-52. [Abstract] [Full-text]
25. Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer.
    Anticancer Drugs, 19(7): 745-8. [Abstract] [Full-text]
26. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer.
    Anticancer Drugs, 19(7): 733-7. [Abstract] [Full-text]
27. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
    Anticancer Drugs, 19(7): 721-7. [Abstract] [Full-text]
28. Aspiration-sclerotherapy results in effective control of liver volume in patients with liver cysts.
    Dig Dis Sci, 53(8): 2251-7. [Abstract] [Full-text]
29. Design of a graphical and interactive interface for facilitating access to drug contraindications, cautions for use, interactions and adverse effects.
    BMC Med Inform Decis Mak, 8: 21. [Abstract] [Full-text]
30. Implementation of quality measures to reduce surgical site infection in colorectal patients.
    Dis Colon Rectum, 51(7): 1004-9. [Abstract] [Full-text]
31. Improvement of meta-tetra(hydroxyphenyl)chlorin-like photosensitizer selectivity with folate-based targeted delivery. synthesis and in vivo delivery studies.
    J Med Chem, 51(13): 3867-77. [Abstract] [Full-text]
32. Organelle-targeted delivery of biological macromolecules using the protein transduction domain: potential applications for Peptide aptamer delivery into the nucleus.
    J Mol Biol, 380(5): 777-82. [Abstract] [Full-text]
33. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events.
    J Am Coll Cardiol, 52(2): 124-31. [Abstract] [Full-text]
34. Treatment of occult reflux lowers the incidence rate of pediatric febrile urinary tract infection.
    Urology, 72(1): 72-6. [Abstract] [Full-text]
35. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.
    Blood, 112(2): 415-25. [Abstract] [Full-text]
36. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection.
    J Allergy Clin Immunol, 122(1): 22-8. [Abstract] [Full-text]
37. Increased incidence of asthma in HIV-infected children treated with highly active antiretroviral therapy in the National Institutes of Health Women and Infants Transmission Study.
    J Allergy Clin Immunol, 122(1): 159-65. [Abstract] [Full-text]
38. Antiretroviral therapy corrects HIV-1-induced expansion of CD8+ CD45RA+ CD2-) CD11a(bright) activated T cells.
    J Allergy Clin Immunol, 122(1): 166-72, 172.e1-2. [Abstract] [Full-text]
39. Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux.
    Gastroenterology, 135(1): 72-81. [Abstract] [Full-text]
40. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
    J Infect, 57(1): 16-32. [Abstract] [Full-text]
41. suPAR associates to glucose metabolic aberration during glucose stimulation in HIV-infected patients on HAART.
    J Infect, 57(1): 55-63. [Abstract] [Full-text]
42. Self-assembled star-shaped chlorin-core poly(varepsilon-caprolactone)-poly(ethylene glycol) diblock copolymer micelles for dual chemo-photodynamic therapies.
    Biomaterials, 29(26): 3599-608. [Abstract] [Full-text]
43. Cationic lipid bilayer coated gold nanoparticles-mediated transfection of mammalian cells.
    Biomaterials, 29(26): 3617-24. [Abstract] [Full-text]
44. Silk polymer-based adenosine release: therapeutic potential for epilepsy.
    Biomaterials, 29(26): 3609-16. [Abstract] [Full-text]
45. Alternating release of different bioactive molecules from a complexation polymer system.
    Biomaterials, 29(26): 3591-8. [Abstract] [Full-text]
46. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
    J Clin Oncol, 26(20): 3411-7. [Abstract] [Full-text]
47. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.
    J Clin Oncol, 26(20): 3351-7. [Abstract] [Full-text]
48. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
    J Clin Oncol, 26(20): 3317-23. [Abstract] [Full-text]
49. Pleth variability index to monitor the respiratory variations in the pulse oximeter plethysmographic waveform amplitude and predict fluid responsiveness in the operating theatre.
    Br J Anaesth, 101(2): 200-6. [Abstract] [Full-text]
50. Influence of systolic-pressure-variation-guided intraoperative fluid management on organ function and oxygen transport.
    Br J Anaesth, 101(2): 194-9. [Abstract] [Full-text]
51. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Oncogene, 27(30): 4161-71. [Abstract] [Full-text]
52. Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa.
    J Clin Pharm Ther, 33(4): 393-400. [Abstract] [Full-text]
53. Factors influencing the use of potentially inappropriate medication in older patients in Slovakia.
    J Clin Pharm Ther, 33(4): 381-92. [Abstract] [Full-text]
54. The potential use of AKAP18delta as a drug target in heart failure patients.
    Expert Opin Biol Ther, 8(8): 1099-108. [Abstract] [Full-text]
55. Biofunctionalized targeted nanoparticles for therapeutic applications.
    Expert Opin Biol Ther, 8(8): 1063-70. [Abstract] [Full-text]
56. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy.
    J Antimicrob Chemother, 62(2): 234-45. [Abstract] [Full-text]
57. Impact of depression on HIV outcomes in the HAART era.
    J Antimicrob Chemother, 62(2): 246-55. [Abstract] [Full-text]
58. Antibiotic prescribing patterns in village health clinics across 10 provinces of Western China.
    J Antimicrob Chemother, 62(2): 410-5. [Abstract] [Full-text]
59. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis.
    Proc Natl Acad Sci U S A, 105(27): 9343-8. [Abstract] [Full-text]
60. Dendrimer hydrazides as multivalent transient inter-cellular linkers.
    Biomaterials, 29(27): 3693-702. [Abstract] [Full-text]
61. Kinetics of the breakdown of cross-linked soy protein films for drug delivery.
    Biomaterials, 29(27): 3750-6. [Abstract] [Full-text]
62. Metabolic syndrome and resistance to IV thrombolysis in middle cerebral artery ischemic stroke.
    Neurology, 71(3): 190-5. [Abstract] [Full-text]
63. Malaria chemoprophylaxis: strategies for risk groups.
    Clin Microbiol Rev, 21(3): 466-72. [Abstract] [Full-text]
64. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis.
    Circulation, 118(3): 258-67. [Abstract] [Full-text]
65. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
    Br J Cancer, 99(2): 294-304. [Abstract] [Full-text]
66. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
    Br J Cancer, 99(2): 275-82. [Abstract] [Full-text]
67. Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma.
    Br J Cancer, 99(2): 253-8. [Abstract] [Full-text]
68. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI).
    Circulation, 118(3): 268-76. [Abstract] [Full-text]
69. Small-molecule protein tyrosine phosphatase inhibition as a neuroprotective treatment after spinal cord injury in adult rats.
    J Neurosci, 28(29): 7293-303. [Abstract] [Full-text]
70. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
    Cancer Res, 68(14): 5519-23. [Abstract] [Full-text]
71. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
    J Clin Oncol, 26(21): 3598-606. [Abstract] [Full-text]
72. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
    J Clin Oncol, 26(21): 3567-72. [Abstract] [Full-text]
73. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
    J Clin Oncol, 26(21): 3523-9. [Abstract] [Full-text]
74. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).
    J Clin Oncol, 26(21): 3511-6. [Abstract] [Full-text]
75. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.
    J Clin Oncol, 26(21): 3487-95. [Abstract] [Full-text]
76. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis.
    J Clin Oncol, 26(21): 3582-9. [Abstract] [Full-text]
77. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
    J Clin Oncol, 26(21): 3614-20. [Abstract] [Full-text]
78. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
    J Clin Oncol, 26(21): 3543-51. [Abstract] [Full-text]
79. Non-Hodgkin lymphoma in women: reproductive factors and exogenous hormone use.
    Am J Epidemiol, 168(3): 278-88. [Abstract] [Full-text]
80. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins.
    Metabolism, 57(8): 1088-92. [Abstract] [Full-text]
81. iNOS as a therapeutic target for treatment of human tumors.
    Nitric Oxide, 19(2): 217-24. [Abstract] [Full-text]
82. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Antiviral Res, 79(3): 143-65. [Abstract] [Full-text]
83. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
    Gynecol Oncol, 110(2): 140-5. [Abstract] [Full-text]
84. Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
    Gynecol Oncol, 110(2): 146-51. [Abstract] [Full-text]
85. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy.
    Gynecol Oncol, 110(2): 190-5. [Abstract] [Full-text]
86. Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts.
    Gynecol Oncol, 110(2): 251-5. [Abstract] [Full-text]
87. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?
    Gynecol Oncol, 110(2): 133-9. [Abstract] [Full-text]
88. HVJ envelope vector, a versatile delivery system: its development, application, and perspectives.
    Biochem Biophys Res Commun, 373(3): 345-9. [Abstract] [Full-text]
89. Chitosan and a modified chitosan as agents to improve performances of mucoadhesive vaginal gels.
    Colloids Surf B Biointerfaces, 66(1): 141-5. [Abstract] [Full-text]
90. Effect of polyethylene glycol on preparation of rifampicin-loaded PLGA microspheres with membrane emulsification technique.
    Colloids Surf B Biointerfaces, 66(1): 65-70. [Abstract] [Full-text]
91. The synthesis of biodegradable graft copolymer cellulose-graft-poly(L-lactide) and the study of its controlled drug release.
    Colloids Surf B Biointerfaces, 66(1): 26-33. [Abstract] [Full-text]
92. Host-directed drug targeting of factors hijacked by pathogens.
    Sci Signal, 1(29): re8. [Abstract] [Full-text]
93. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies.
    Sex Transm Infect, 84: i31-i36. [Abstract] [Full-text]
94. Gastric varices with gastrorenal shunt: combined therapy using transjugular retrograde obliteration and partial splenic embolization.
    AJR Am J Roentgenol, 191(2): 555-9. [Abstract] [Full-text]
95. A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants.
    Int J Cancer, 123(6): 1457-65. [Abstract] [Full-text]
96. Self-assembling cyclodextrin based hydrogels for the sustained delivery of hydrophobic drugs.
    J Biomed Mater Res A, 86(3): 736-48. [Abstract] [Full-text]
97. Novel silica-coated iron-carbon composite particles and their targeting effect as a drug carrier.
    J Biomed Mater Res A, 86(3): 671-7. [Abstract] [Full-text]
98. The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.
    Leuk Res, 32(11): 1698-708. [Abstract] [Full-text]
99. Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
    Leuk Res, 32(11): 1674-83. [Abstract] [Full-text]
100. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
     Blood, 112(3): 793-804. [Abstract] [Full-text]
101. Intracellular protein delivery activity of peptides derived from insulin-like growth factor binding proteins 3 and 5.
     Exp Cell Res, 314(13): 2352-61. [Abstract] [Full-text]
102. SCKs as nanoparticle carriers of doxorubicin: investigation of core composition on the loading, release and cytotoxicity profiles.
     Chem Commun (Camb). [Abstract] [Full-text]
103. RAFT polymerization: an avenue to functional polymeric micelles for drug delivery.
     Chem Commun (Camb). [Abstract] [Full-text]
104. Pancreatic cancer: from molecular pathogenesis to targeted therapy.
     Cancer Metastasis Rev, 27(3): 495-522. [Abstract] [Full-text]
105. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.
     Lancet, 372(9635): 293-9. [Abstract] [Full-text]
106. Long-term outcome of primary angioplasty compared with fibrinolysis across age groups: a Danish Multicenter Randomized Study on Fibrinolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2) substudy.
     Am Heart J, 156(2): 391-6. [Abstract] [Full-text]
107. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery.
     Am Heart J, 156(2): 373.e9-16. [Abstract] [Full-text]
108. Modulate photoinduced electron transfer efficiency of bipolar dendritic systems.
     Org Lett, 10(15): 3211-4. [Abstract] [Full-text]
109. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 2: residual conjunctival flora.
     J Cataract Refract Surg, 34(8): 1383-8. [Abstract] [Full-text]
110. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 1: aqueous concentration of moxifloxacin.
     J Cataract Refract Surg, 34(8): 1379-82. [Abstract] [Full-text]
111. Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus.
     Cancer, 113(3): 470-6. [Abstract] [Full-text]
112. Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer.
     Hum Pathol, 39(8): 1221-8. [Abstract] [Full-text]
113. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
     Am J Ophthalmol, 146(2): 285-291. [Abstract] [Full-text]
114. Delayed emotional recovery after taxane-based chemotherapy.
     Cancer, 113(3): 638-47. [Abstract] [Full-text]
115. External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial.
     Cancer, 113(3): 559-65. [Abstract] [Full-text]
116. How do patient expectancies, quality of life, and postchemotherapy nausea interrelate?
     Cancer, 113(3): 654-61. [Abstract] [Full-text]
117. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.
     Cancer, 113(3): 573-81. [Abstract] [Full-text]
118. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
     Cancer, 113(3): 542-6. [Abstract] [Full-text]
119. Process considerations related to the microencapsulation of plasmid DNA via ultrasonic atomization.
     Biotechnol Bioeng, 101(1): 172-81. [Abstract] [Full-text]
120. Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
     Breast Cancer Res Treat, 111(2): 203-8. [Abstract] [Full-text]
121. Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100.
     Breast Cancer Res Treat, 111(2): 261-7. [Abstract] [Full-text]
122. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis.
     CMAJ, 179(3): 235-44. [Abstract] [Full-text]
123. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections.
     Arch Intern Med, 168(14): 1585-91. [Abstract] [Full-text]
124. A steep increase in domestic fatal medication errors with use of alcohol and/or street drugs.
     Arch Intern Med, 168(14): 1561-6. [Abstract] [Full-text]
125. Sialyl alpha(2-->3) lactose clusters using carbosilane dendrimer core scaffolds as influenza hemagglutinin blockers.
     Bioorg Med Chem Lett, 18(15): 4405-8. [Abstract] [Full-text]
126. Molecular modeling of a PAMAM-CGS21680 dendrimer bound to an A2A adenosine receptor homodimer.
     Bioorg Med Chem Lett, 18(15): 4312-5. [Abstract] [Full-text]
127. Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE).
     Stroke, 39(8): 2257-63. [Abstract] [Full-text]
128. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
     Ann Oncol, 19(8): 1450-7. [Abstract] [Full-text]
129. Early disruption of the blood-brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke.
     Stroke, 39(8): 2385-7. [Abstract] [Full-text]
130. Optimizing postprandial glycemia in pediatric patients with type 1 diabetes using insulin pump therapy: impact of glycemic index and prandial bolus type.
     Diabetes Care, 31(8): 1491-5. [Abstract] [Full-text]
131. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.
     Ann Oncol, 19(8): 1442-9. [Abstract] [Full-text]
132. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.
     Ann Oncol, 19(8): 1470-6. [Abstract] [Full-text]
133. Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor.
     Ann Oncol, 19(8): 1435-41. [Abstract] [Full-text]
134. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
     Ann Oncol, 19(8): 1417-22. [Abstract] [Full-text]
135. A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.
     Ann Oncol, 19(8): 1465-9. [Abstract] [Full-text]
136. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer.
     Ann Oncol, 19(8): 1393-401. [Abstract] [Full-text]
137. UFT (tegafur-uracil) in rectal cancer.
     Ann Oncol, 19(8): 1371-8. [Abstract] [Full-text]
138. Distinctive in vitro effects of T-cell growth cytokines on cytomegalovirus-stimulated T-cell responses of HIV-infected HAART recipients.
     Virology, 378(1): 48-57. [Abstract] [Full-text]
139. Documentation of drug allergy on drug chart in patients presenting for surgery.
     Ir J Med Sci, 177(3): 243-5. [Abstract] [Full-text]
140. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer.
     Br J Cancer, 99(3): 442-7. [Abstract] [Full-text]
141. Tumour-targeted nanomedicines: principles and practice.
     Br J Cancer, 99(3): 392-7. [Abstract] [Full-text]
142. Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).
     Ann Hematol, 87(9): 717-26. [Abstract] [Full-text]
143. Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients.
     Ann Hematol, 87(9): 727-34. [Abstract] [Full-text]
144. Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism.
     Curr Opin Pulm Med, 14(5): 422-6. [Abstract] [Full-text]
145. Drug-prescribing patterns during pregnancy in the tertiary care hospitals of Pakistan: a cross sectional study.
     BMC Pregnancy Childbirth, 8: 24. [Abstract] [Full-text]
146. Timing of preoperative antibiotic prophylaxis: a modifiable risk factor for deep surgical site infections after pediatric spinal fusion.
     Pediatr Infect Dis J, 27(8): 704-8. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.